Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical site organization, today announces it has made three C-suite hires, as the company continues to dramatically expand its clinical site and patient organization, bringing research opportunities to more people.
Nick Campbell joins as Chief Commercial Officer, Nick Spittal is the company's new Chief Operating Officer, and Steph Anderson has been promoted to Chief of Staff. All three will be members of the executive leadership team.
Dr. Paul Evans, Chief Executive and President of Velocity, said, “Velocity is uncompromising on quality and that extends to the talent we hire. We are transforming the clinical sites business, creating a pro-innovation and people-centered environment and we need the right people to help us do that. I am confident these new appointments will greatly help Velocity in its next phase. We continue to open more dedicated-research sites, expand our embedded model, and connect patients with the pharmaceutical industry — all with the hope of improving lives and speeding up drug development.”
Nick Campbell (LinkedIn) joins Velocity as Chief Commercial Officer with over 20 years in the pharmaceutical industry across Europe, Asia and North America, encompassing all phases of clinical research. He gained extensive experience of contract research organization (CRO) sales at both Covance and IQVIA, before spending the last six years in high-growth technology companies, assuming Board-level positions.
Nick Spittal (LinkedIn) will be Velocity’s Chief Operating Officer and joins from Syneos Health where he was Executive Vice President and General Manager of CNS Clinical Development. He has spent over 20 years in the clinical research space, including roles of increasing seniority with Inveresk, Charles River, Kendle, Chiltern, ZeeCRO, and INC Research. Nick is a certified Project Management Professional with the Project Management Institute.
Steph Anderson (LinkedIn) has been promoted internally to Chief of Staff and will become a full time member of the Executive Leadership Team (ELT). She was previously Chief People Officer at Meridian Clinical Research and has spent over a decade in the healthcare and tech industry. Since Velocity acquired Meridian in December 2022, Steph has played a critical role leading the integration of the two companies.
In December 2022, Velocity acquired Meridian to become the largest clinical research site organization globally. Velocity’s sites are fully integrated via a centralized infrastructure and common technology backbone, allowing for superior patient enrollment and consistent, high-quality data delivery. As a result, CROs and drug developers can benefit from simplified access to high-performance research sites internationally, speeding up product development.
About Velocity Clinical Research
Headquartered in Durham, NC, Velocity Clinical Research is the leading multi-speciality clinical trials organization. With more than 80 fully integrated sites, 220 investigators and over one million patients in its network, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and wellbeing.
Velocity offers unified research site solutions to provide the right patients, investigators, and research staff for Phase 1-4 clinical trials across the U.S. and Europe. The company also operates a technology hub in India, where it is unlocking a new era in clinical research by developing innovative systems to leverage expansive site, patient, and historical performance data.
Velocity has supported more than 15,000 studies, and is committed to delivering timely, high-quality data and unparalleled patient care. To learn more, visit velocityclinical.com.